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Introduction Remifentanil is an opioid with a unique
pharmacokinetic profile. Its organ-independent elimination and
short context-sensitive half time of 3 to 4 minutes lead to a highly
predictable offset of action. We tested the hypothesis that with
an analgesia-based sedation regimen with remifentanil and
propofol, patients after cardiac surgery reach predefined criteria
for discharge from the intensive care unit (ICU) sooner, resulting
in shorter duration of time spent in the ICU, compared to a
conventional regimen consisting of midazolam and fentanyl. In
addition, the two regimens were compared regarding their
costs.
Methods In this prospective, open-label, randomised, single-
centre study, a total of 80 patients (18 to 75 years old), who had
undergone cardiac surgery, were postoperatively assigned to
one of two treatment regimens for sedation in the ICU for 12 to
72 hours. Patients in the remifentanil/propofol group received
remifentanil (6- max. 60 µg kg-1  h-1; dose exceeds
recommended labelling). Propofol (0.5 to 4.0 mg kg-1 h-1) was
supplemented only in the case of insufficient sedation at
maximal remifentanil dose. Patients in the midazolam/fentanyl
group received midazolam (0.02 to 0.2 mg kg-1 h-1) and fentanyl
(1.0 to 7.0 µg kg-1 h-1). For treatment of pain after extubation,
both groups received morphine and/or non-opioid analgesics.
Results The time intervals (mean values ± standard deviation)
from arrival at the ICU until extubation (20.7 ± 5.2 hours versus
24.2 h ± 7.0 hours) and from arrival until eligible discharge from
the ICU (46.1 ± 22.0 hours versus 62.4 ± 27.2 hours) were
significantly (p  < 0.05) shorter in the remifentanil/propofol
group. Overall costs of the ICU stay per patient were equal
(approximately €1,700 on average).
Conclusion Compared with midazolam/fentanyl, a remifentanil-
based regimen for analgesia and sedation supplemented with
propofol significantly reduced the time on mechanical ventilation
and allowed earlier discharge from the ICU, at equal overall
costs.
Introduction
In western industrialised countries, a substantial amount of the
gross domestic product is spent on health care; for example,
almost 11% in Germany. About 30% of the health care
expenditure is caused by inpatient curative and rehabilitative
care [1]. Intensive care units (ICUs) are among the costliest
areas of the hospital. Personnel costs account for an esti-
mated 35% to 60% of the ICU budget and pharmacy costs for
10% to 23%. Sedatives and analgesics only constitute
approximately 1% to 3.5% of the ICU costs [2].
The major goals of analgesia and sedation for critically ill
patients in the ICU are to provide control of pain and anxiolysis
and to facilitate mechanical ventilation and therapeutic and
diagnostic interventions. Patients should be easily arousable,
calm and co-operative [3]. Mostly, a combination of an opioid,
such as fentanyl, sufentanil or morphine, to provide analgesia
and a benzodiazepine or propofol to provide sedation is used.
When administered over several hours or even days, however,
elimination of most drugs for analgesia and sedation may be
prolonged in critically ill patients as a result of accumulation
ASA = American Society of Anesthesiologists; BPS = Behavioural Pain Scale; FiO2 = fraction of inspired oxygen; ICU = intensive care unit; paCO2 
= partial pressure of carbon dioxide in arterial blood; paO2 = partial pressure of oxygen in arterial blood; SAPS = simplified acute physiology score; 
SPC = summary of product characteristics; RASS = Richmond Agitation Sedation Scale; VAS = Visual Analogue Scale.Critical Care    Vol 10 No 3    Muellejans et al.
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due to organ-dependent elimination. This can result in delayed
emergence from sedation after discontinuation of administra-
tion, increased time on the ventilator and in the ICU and, there-
fore, increased costs [4]. Moreover, prolonged sedation may
have not only economic but also medical consequences, such
as failure to recognize cerebral insult, immunosuppression or
venous stasis, which may promote thromboembolism [4,5].
Remifentanil hydrochloride is a potent, selective µ-opioid
receptor agonist, indicated for the provision of analgesia in
mechanically ventilated critically ill patients for up to three
days. Its organ-independent elimination and short context-sen-
sitive half time of 3 to 4 minutes lead to a highly predictable off-
set of action [6].
These properties make remifentanil a useful analgesic in criti-
cally ill patients requiring analgesia and sedation. Several stud-
ies have been published describing the potential role and
actual use of remifentanil in the ICU [7-10]. Several recently
published studies showed that the use of remifentanil can
result in shorter time to extubation in comparison to morphine
[11,12], fentanyl [12] and sufentanil [13]. From a pharmaco-
logical view, propofol is the best concomitant sedative for
remifentanil, as it leads to shorter awakening times than mida-
zolam [14]. Recently published German guidelines recom-
mend the use of short acting drugs for analgesia and sedation
for less than 24 hours [15].
In our study, midazolam/fentanyl was chosen as the compara-
tor-regimen for two reasons: first, with regard to the direct
drug costs, it is the cheapest alternative; and second, it is the
most widely used regimen in German ICUs [16]. Cardiac sur-
gical patients were selected because the ICU bed is often the
'bottleneck' leading to postponement of surgical procedures.
Speeding the recovery process would lead to a higher turno-
ver of patients, reduced costs per patient, less postponed
operations and to a more efficient use of ICU resources.
This clinical and cost-consequence study was designed to
compare a remifentanil-based sedation regimen supple-
mented with propofol with a conventional midazolam/fentanyl
regimen in patients after cardiac surgery requiring postopera-
tive mechanical ventilation in the ICU.
Materials and methods
This randomised, open-label, single-centre, parallel group
study was conducted in accordance with good clinical prac-
tice and with the guidelines set out in the Declaration of Hel-
sinki. After local ethics committee approval, a total of 80
patients were recruited. Preoperatively, informed consent was
obtained from all patients.
Patients who had undergone elective coronary artery and/or
heart valve surgery were eligible for entry into the study if they
were aged 18 to 75 years, were intubated and were expected
to require mechanical ventilation for 12 to 72 hours.
Patients were excluded from the study if one of the following
conditions was given or expected to become applicable: pre-
existing impaired central nervous system function, weight
>120 kg, use of neuromuscular blocking agents in the ICU,
epidural anaesthesia, ASA (American Society of Anesthesiol-
ogists) IV and V. Patients with a history of allergy to study med-
ication or of opioid abuse were also excluded from the study.
Patients who required analgesia and sedation beyond 72
hours or a tracheostomy and pregnant or lactating women
were excluded from the study.
Double blinding was judged to be impractical due to the differ-
ent dosing algorithms and physical characteristics of the
drugs used. Furthermore, in a double-blinded study the medi-
cal staff would most probably have recognized the regimen at
discontinuation of study drugs due to their diverging pharma-
cokinetic properties.
Anaesthesia for cardiac surgery was performed in both groups
according to routine practice in the study centre, with a total
intravenous technique consisting of remifentanil, propofol, clo-
nidine and cisatracurium. After termination of the operation,
remifentanil was continued at the investigator's discretion to
maintain analgesia during the transfer of patients to the ICU.
The propofol infusion was stopped on arrival at the ICU at the
latest.
After arrival in the ICU, patients were randomised on a 1:1
basis to receive either remifentanil (n = 40), titrated to provide
optimal analgesia and supplemented with propofol if additional
sedation was required, or a conventional treatment regimen
consisting of midazolam and fentanyl (n = 40), administered
simultaneously and then titrated to response. The doses of
propofol, midazolam and fentanyl were in accordance with the
guidelines of the Society of Critical Care Medicine [14]. The
maximum remifentanil dose was higher than the maximum
dose recommended in the SPC to provide effective analgesia-
based sedation in this group.
According to the clinic's usual practice, the level of sedation
was judged according to a simple three-step sedation score
(Table 1) and the dosing of the sedative agents was adapted
accordingly.
Treatment protocols
Remifentanil-based analgesia and sedation
On arrival on the ICU, the remifentanil infusion was continued
or started at an initial rate of 6 to 12 µg kg-1 h-1 and was
increased depending on clinical need up to a maximum of 60
µg kg-1 h-1. If an adequate level of sedation was not achieved
with remifentanil alone at an infusion rate of 60 µg kg-1 h-1,
additional sedation was provided by administering a bolusAvailable online http://ccforum.com/content/10/3/R91
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dose of propofol (0.3 to 1.0 mg kg-1) and/or a propofol infusion
starting at a rate of 0.5 to 1.0 mg kg-1 h-1. If the adequate level
of sedation was still not achieved, the patient received addi-
tional boluses and/or increases in the infusion rate of propofol
up to a maximum dose of 4 mg kg-1 h-1. In the case of excessive
sedation, the propofol infusion rate was reduced first.
Hypnotic-based sedation with midazolam/fentanyl
At arrival on the ICU, patients received an initial bolus dose of
fentanyl of 1 to 2 µg kg-1, followed by an infusion at an initial
rate of 1 to 2 µg kg-1 h-1. Additionally, all patients received an
initial bolus dose of midazolam. Although this bolus could
range from 0.03 to 0.2 mg kg-1, patients commonly received a
2 mg bolus at the lower end of this range. This was followed
by an infusion at an initial rate of 0.02 to 0.04 mg kg-1 h-1.
In case of insufficient sedation, additional bolus doses of mida-
zolam were given and/or the midazolam infusion was
increased up to a maximum of 0.2 mg kg-1 h-1. In the case of
insufficient analgesia, fentanyl was increased up to a maximum
of 7 µg kg-1 h-1.
Weaning, extubation and discharge
Only patients who were expected to require mechanical venti-
lation for at least 12 hours were included in the study. The
weaning process was started on the morning after the day of
the operation at 0700 hours if no surgical complication was
anticipated, if there were no signs of respiratory or haemody-
namic impairment or acute organ insufficiency and if the rectal
body temperature was >36.5°C. When weaning was started,
all infusions were stopped and patients in the remifentanil/pro-
pofol group received a bolus of morphine (0.1 to 0.3 mg/kg).
For treatment of pain after extubation, both groups received
morphine (a bolus of 0.1 to 0.3 mg/kg) and/or other analge-
sics, at the investigator's discretion. Extubation was performed
if there were no signs of major respiratory (tidal volume >4 ml/
kg, respiratory rate 10 to 25/minute, paO2 (partial pressure of
oxygen in arterial blood)>69 mmHg, paCO2 (partial pressure
of carbon dioxide in arterial blood)<55 mmHg, FIO2 (fraction of
inspired oxygen)<0.5) or of haemodynamic impairment and if
the patient was able to follow commands.
Discharge from the ICU was performed if there were no signs
of neurological (Ramsay sedation score 2, co-operative, ori-
ented, tranquil), respiratory (paO2 >69 mmHg, paCO2 = 35 to
45 mmHg, inspired O2 <3 l/minute), haemodynamic (no cate-
cholamines, no significant fluid deficit) or surgical (no antici-
pated surgical complication) impairment and if the pain score
on the visual analogue scale (VAS) was <4.
Table 1
Three-step sedation score
Step Level of sedation Definition
1 Insufficient Patient moves or grimaces without stimuli, patient is coughing 
or lacrimates
2 Adequate Patient is calm, moves on stimuli
3 Excessive Patient does not react to stimuli
Table 2
Patient demography and baseline characteristics
Remifentanil/propofol Midazolam/fentanyl
Number of patients analysed 39 33
Mean age (years) 65 ± 8.1 66.5 ± 7.0
Male/female 30/9 23/10
Mean height (cm)/weight (kg) 169.9 ± 8.8/80.1 ± 12.7 170.5 ± 7.1/83.9 ± 12.1
ASA physical status (I/II/III) 0/0/39 0/0/33
Type of surgerya
Bypass surgery 33 31
Valve surgery 11 8
Mean ejection fraction (%) at screening 49.5 ± 12.7 50.3 ± 15.8
Mean SAPS II on admission 37.6 ± 14.2 28.2 ± 11.7
Values are number of patients or mean ± standard deviation. aMultiple counts are possible per subject. SAPS, simplified acute physiology score.Critical Care    Vol 10 No 3    Muellejans et al.
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Efficacy assessment points
To assess the efficacy of the two regimens, several time points
were recorded throughout the treatment period (Figure 1). The
time to the start of the weaning procedure was defined as the
time from arrival on the ICU to the first time the study drug was
reduced in order to encourage spontaneous respiration, which
subsequently led to extubation. The weaning time was
recorded, calculated as the time interval from start of the
weaning until extubation. Finally, time intervals from arrival on
the ICU until extubation and eligibility for (primary end point)
and actual discharge from ICU were recorded.
Safety
Adverse events, defined as any untoward medical occurrence
in a patient administered a pharmaceutical product and that
does not necessarily have a causal relationship with this treat-
ment, were recorded from the start of the study drug until dis-
charge from ICU. Serious adverse events were defined as
adverse events that resulted in any of the following outcomes:
death, life-threatening event, prolongation of hospitalisation, or
a disability or incapacity. Important medical events that did not
result in death or were not life-threatening were also consid-
ered serious adverse events when, on the basis of appropriate
medical judgement, they jeopardised the patient and required
medical or surgical intervention to prevent one of the out-
comes listed above.
Cost calculation
Drug costs (including all concomitant medication and wast-
age), costs of materials for analgo-sedation (only variable
costs), and personnel costs in the ICU were considered. All
other types of costs were assumed to not significantly differ
between regimens. Indirect costs (productivity loss) were
excluded. The resource utilisation was derived from the study
centre. Generic unit costs (price level 2003) based on publicly
available databases [17-19] were applied for resource valua-
tion. The financial department of the study centre checked
these unit costs to ensure that they represent realistic
estimates.
Official ex-factory prices were used for the calculation of drug
costs (e.g., costs of study drugs: remifentanil €5.36/mg, pro-
pofol €19.34/g, fentanyl €5.42/mg and midazolam €0.124/
mg) [17]. For the costs of blood products official hospital tar-
iffs [18] were applied, while for the costs of materials the aver-
age unit costs from two hospitals and two internet shops were
taken. Personnel costs on the ICU were calculated based on
the times measured in the study and on cost rates per hour
and patient, which were different for physicians and nurses.
The cost rates are based on specific, real-world cost rates
from a German 400 bed hospital [19] that were extrapolated
to 2003 [20,21]. The resulting cost rates were €6.19 or
€15.68 per hour of care per patient for physicians and nurses,
respectively. As personnel costs vary during ICU stay depend-
ing on the intensity of care, the ICU stay was divided into three
periods (ventilation period (including weaning), treatment
period (intensive care activities other than ventilation), and
monitoring only period), and the respective personnel-cost-
multipliers were applied (1.00, 1.00, 0.67, respectively, for
physicians; 1.71, 1.00, 0.57, respectively, for nurses)
according to the calculation of German Diagnosis Related
Groups [22].
Statistics
At the planning state of this study only very limited data regard-
ing the expected difference between the two groups and their
variability had been published with regard to the primary end-
point. Therefore, a two-stage adaptive study design according
to Bauer and Köhne [23] was used. Based on an interim anal-
ysis with 30 patients, standard deviation and effect size were
estimated. Based on these data, it was determined by the
planning statistician to recruit at least 40 additional patients in
the second stage. If all patients of the second stage were eval-
uable for the primary efficacy variable, the total sample size
should guarantee a global power of at least 80% for a stand-
ardised effect size of 0.7, which was deemed a reasonable
setting according to the interim analysis. Due to the loss of
power when using Fisher's combination of p values as the glo-
bal test, formally a power of 83% and an adjusted alpha had
to be used for sample size estimation for the second stage. To
show superiority of the remifentanil regimen in the final analy-
sis at the 5% significance level, the product of two one-sided
p values, associated with the respective t tests for the two
parts of the study, was compared with a critical value of
0.0087 [23].
This combination test was used for the primary efficacy varia-
ble only. For all other tests the interim analysis did not lead to
further adjustments.
Adverse event rates were compared by Fisher's exact test.
Length of time periods and costs were analysed by means of
t-tests. For ordinal data (like the simplified acute physiology
score (SAPS)) the Wilcoxon rank-sum test was used. As
usual, all secondary statistical tests should be interpreted in a
descriptive manner only.
Figure 1
Recorded time points from arrival on the intensive care unit to  discharge Recorded time points from arrival on the intensive care unit to 
discharge.Available online http://ccforum.com/content/10/3/R91
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Scenario and sensitivity analysis
A decision analysis model representing the study was built. It
was employed to simulate the results gained with a different
remifentanil/propofol regimen and to explore the robustness of
the results for modelling parameter variations.
Results
A total of 80 patients were enrolled in the study, of which 72
could be evaluated (modified intent-to-treat population). Of
these, 8 patients (7 patients in the midazolam/fentanyl and 1
patient in the remifentanil/propofol group) had to be excluded
during the study: 3 patients due to mechanical ventilation >72
hours, 4 patients due to reintubation and 1 patient because he
was only randomised but did not receive study medication due
to postoperative bleeding. The seven treated patients were
excluded because the primary efficacy measure could not be
assessed due to a lack of essential data. Demographic and
baseline characteristics are shown in Table 2. Apart from a
higher SAPS II on admission in the remifentanil/propofol group
(p  < 0.05, Wilcoxon rank-sum test), patients were well
matched in the two treatment groups.
Table 3 presents the incidence of adverse events. There was
no statistically significant difference between the remifentanil/
propofol group and the midazolam/fentanyl group in terms of
the overall number of subjects with adverse events (23 versus
24 patients) or serious adverse events (4 versus 6 patients).
Significantly more patients in the remifentanil/propofol group
than in the midazolam/fentanyl group suffered from drug-
related adverse events.
Similarly, the mean percentage time of adequate, inadequate
or excessive sedation between the remifentanil/propofol and
the midazolam/fentanyl group did not differ statistically signifi-
cantly (59% versus 70%, 13% versus 11% and 28% versus
19%, respectively) when compared by means of the t test.
Propofol was added in 21 (54%) of the 39 patients receiving
remifentanil. The mean infusion rates including bolus doses
were 41.2 µg kg-1 h-1 for remifentanil (bolus doses were not
allowed), 2.2 mg kg-1 h-1 for propofol in patients receiving pro-
pofol (which results in a mean of 1.2 kg-1 h-1 propofol for all
patients in the remifentanil/propofol group), 0.06 mg kg-1 h-1
for midazolam and 3.8 µg kg-1 h-1 for fentanyl.
Table 4 presents the time intervals from arrival on ICU to
assessment points and Table 5 shows the costs by category.
Because of the study protocol, the used remifentanil doses
(equivalent to baseline) were higher than in routine clinical
practice. To estimate the costs under routine circumstances,
we performed a scenario analysis. We lowered the mean
remifentanil infusion rate from 41.2 µg kg-1 h-1 to 9 µg kg-1 h-1,
increased the propofol infusion rate from 1.2 mg kg-1 h-1 to 4
mg kg-1 h-1 and assumed that this routine practice scenario
would have rendered the same reduction (24%) in personnel
costs compared to the midazolam/fentanyl regimen and iden-
tical material and drug use (without study drugs) as the base-
line. This scenario led to 56% lower remifentanil/propofol drug
costs or net savings of €214 per patient when compared to
baseline or to the midazolam/fentanyl regimen, respectively. In
Table 3
Adverse event profile
Remifentanil/propofol (n = 40) Midazolam/fentanyl (n = 39) P valuea
Any adverse event 23 24 NS
Any drug-related adverse event 9 2 <0.05
Shivering 8 2 NS
Pain 20 N S
Any serious adverse event 4 6 NS
Any drug-related serious adverse event 0 0 NS
Most commonly occurring adverse events (≥ 5% of patients)
Shivering 14 6 NS
Delirium 7 9 NS
Pain 3 0 NS
Tachycardia 2 0 NS
Neuropathy (nerve injury, e.g., by compression) 1 2 NS
Respiratory insufficiency 0 3 NS
Hypotension 3 0 NS
Haemorrhage 2 2 NS
Values are number of patients with event; multiple entries per patient possible.
aFisher's exact test, two tails, significance level 0.05. NS, not significant.Critical Care    Vol 10 No 3    Muellejans et al.
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addition, the model analysis showed that with the routine
remifentanil/propofol doses, even a personnel cost reduction
of 10% would be sufficient to render cost savings. The univar-
iate sensitivity analysis demonstrated that variations in nurse
and study drug costs might have a strong impact on our cost
results.
Discussion
Sedation on the ICU can be either analgesia or sedative
based. With a sedative-based regimen, hypnotic agents are
titrated to maintain patient comfort despite them having almost
no analgesic effect, and the opioid dose is usually minimised.
Patients are therefore kept asleep but are not necessarily pain
free. When interviewed about their ICU stay, many patients
recall significant unrelieved pain [24-26]. Pain may evoke a
stress response leading to adverse effects such as tachycar-
dia, increased myocardial oxygen consumption, hypercoagula-
bility, immunosuppression and persistent catabolism [14,27].
Moreover, a sedative-based regimen may facilitate overseda-
tion, which may lead to prolonged mechanical ventilation and
longer stays in both the ICU and hospital [4]. The increased
duration of mechanical ventilation may translate into nosoco-
mial complications, such as ventilator-associated pneumonia
[28]. Over-sedation may impede a recommended [29] daily
interruption or lightening of sedation, increase the incidence of
complications [5], hinder neurological assessment and
increase costs through the need for a greater number of
expensive tests such as CT scans of the brain [30].
The aim of analgesia-based sedation is to focus in the first
instance on achieving effective analgesia, with a sedative
agent being given subsequently if required. Effective analgesia
may diminish the stress response, provide comfort, and facili-
tate treatment of critically ill septic patients. Guidelines recom-
mend that sedation of critically ill patients should be started
only after providing adequate analgesia [14,15,31,32].
The ideal sedative agent should be effective and easily titrata-
ble, with a rapid onset and offset of action, no accumulation,
and it should be cost-effective by improving the quality of care,
reducing the time spent on mechanical ventilation or reducing
the length of stay in the ICU [4]. Except for higher acquisition
costs, remifentanil fulfils these attributes.
We have shown that after cardiac surgery, analgesia-based
sedation with remifentanil and propofol allows a facilitated
turnover of patients, achieved by significantly earlier extubation
and discharge from the ICU, and can be administered at equal
total costs, compared with a conventional sedation regimen
with midazolam and fentanyl. Although both remifentanil and
propofol are considerably more expensive than midazolam and
fentanyl, the cost savings achieved by a shorter weaning time,
leading to earlier extubation and an earlier discharge from the
Table 4
Time assessment points
Time assessment point (hours) Remifentanil/propofol (n = 39) Midazolam/fentanyl (n = 33) P valuea
Time from arrival on ICU to weaning 18.5 ± 2.5 18.5 ± 2.2 NS
Weaning time 2.2 ± 4.3 5.7 ± 6.6 <0.05
Time from arrival on ICU to extubation 20.7 ± 5.2 24.2 ± 7.0 <0.05
Time from extubation to eligible ICU discharge 25.4 ± 19.7 38.2 ± 26.3 <0.05
Time from arrival on ICU to eligible ICU dischargeb 46.1 ± 22.0 62.4 ± 27.2 <0.05
Time from arrival on ICU to actual ICU discharge 46.4 ± 21.9 64.7 ± 29.3 <0.05
Values are means ± standard deviation. at test. bPrimary endpoint. ICU, intensive care unit; NS, not significant.
Table 5
Overall costs (€, 2003 price level) of the intensive care unit stay per patient
Remifentanil/propofol (n = 39) Midazolam/fentanyl (n = 33) P valuea
Material 11/10 (5–25) 11/11 (4–18) NS
Non-study drugs 218/137 (31–1257) 192/153 (55–723) NS
Study drugs 353/341 (54–835) 42/46 (19–63) <0.05
Nurses 869/827 (517–2213) 1,131/1,071 (554–2,164) <0.05
Physicians 260/243 (135–723) 352/301 (151–811) <0.05
Overall 1,712/1,558 (1,058–3,647) 1,729/1,604 (821–3,337) NS
Values are means/medians (range). aWilcoxon rank-sum test. NS, not significant.Available online http://ccforum.com/content/10/3/R91
Page 7 of 9
(page number not for citation purposes)
ICU, outweigh the higher acquisition costs. No difference
between the two groups in the level of sedation or in safety
was observed.
The shorter weaning time with remifentanil/propofol is a direct
consequence of the pharmacokinetic profile of these two
drugs. Remifentanil has a rapid onset (1 minute) and offset
(half time <10 minutes) of action [33]. Its organ-independent
metabolism by non-specific blood and tissue esterases results
in a pharmacokinetic profile unaffected by impaired kidney
[9,34] or liver [35] function, which differentiates remifentanil
from all other opioids. Remifentanil does not accumulate, even
after prolonged infusion [36,37].
Although both midazolam and fentanyl have a rapid onset and
a short clinical duration with single doses, accumulation and
prolonged sedative effects may be observed after continuous
administration [38], which is also indicated by a significantly
longer context-sensitive half time of these drugs [36,39].
Time from extubation (after discontinuation of the study medi-
cation) until discharge from the ICU was also significantly
longer in the midazolam/fentanyl group. This recovery period
after a long and difficult operation, such as open heart surgery
with cardiopulmonary bypass in elderly patients with multiple
co-morbidities, certainly is a multi-factorial event. Although
patients in the remifentanil/propofol group were more severely
ill, as shown by a higher SAPS II, a difference in vigilance, ori-
entation and compliance after extubation was obvious.
Patients in the midazolam/fentanyl group reached the prede-
fined discharge criteria later. An accumulation of sedatives
most likely can be presumed to be the reason.
With respect to adverse and serious adverse events and the
duration of adequate sedation, no statistically significant differ-
ences could be determined. These findings correspond well
with the published literature [12]. The higher incidence of
drug-related adverse events in the remifentanil/propofol
group, mainly consisting of shivering, might be due to the unu-
sually high remifentanil dose in our study and is not consistent
with the findings of other studies [8,12].
As pointed out, the mean infusion rate for remifentanil was very
high (41.2 µg kg-1 h-1), leading to very high drug costs. The
summary of product characteristics of remifentanil recom-
mends a starting dose of 6 to 9 µg kg-1 h-1 and the addition of
a sedative drug already at a rate of 12 µg kg-1 h-1. In our study,
in spite of a very high remifentanil infusion rate of 60 µg kg-1 h-
1, more than half of the patients still needed the addition of pro-
pofol. Presumably, the earlier addition of propofol, following
the recommendations in the summary of product characteris-
tics of remifentanil, would have considerably reduced the drug
costs of remifentanil, with only a smaller increase in the costs
for propofol. As demonstrated in our scenario analysis, this
real world scenario might even render cost savings to the hos-
pital. This assumption is further supported by a recently pub-
lished study in which the mean remifentanil infusion rate was
7.8 µg kg-1 h-1, with a remifentanil 'trigger' dose for the addition
of midazolam of 12 µg kg-1 h-1 [11]. In this study, extubation
could be performed within 17 minutes after a duration of
mechanical ventilation of more than 14 hours.
In addition to this cost-reducing consideration, according to
the study protocol, a high concentration of 250 µg/ml remifen-
tanil in the infusion syringes (10 mg remifentanil in 40 ml infu-
sion solution) led to high wastage costs of remifentanil, which
are included in the drug costs. A lower concentration certainly
would reduce wastage costs and should be recommended in
short term sedation.
Our study shows several limitations: as in any open study,
there is the risk of biased patient assessment and treatment.
On the other hand, an open study design offers the opportu-
nity to investigate the drugs under real world conditions, that
is, it measures the effectiveness instead of the efficacy.
When the protocol was being designed, we felt that it might
be more feasible to use a three point scale instead of a vali-
dated sedation scale like the Sedation-Agitation Scale (SAS)
or the Richmond Agitation Sedation Scale (RASS) for evaluat-
ing sedation, or the Visual Analogue Scale (VAS) or the
Behavioural Pain Scale (BPS) for evaluating pain. To date, we
would also prefer to use these validated scales.
Concomitant medications were not limited and not recorded,
and data on tolerance and withdrawal were not collected in
our trial.
According to standardised processes of the hospital, weaning
was started on the morning after the operation at 0700. This
was fixed due to an established one-shift system for physicians
in the study centre and ensured close assessments in regard
to extubation and discharge criteria during the daytime. This
procedure led to longer postoperative mechanical ventilation
and sedation than a fast track regimen, resulting in a mean
time to weaning of more than 18 hours in both groups. A three-
shift system would likely have enabled an earlier weaning,
which might have had impact on time to extubation and dis-
charge in both groups. However, the applied procedure
resulted in the positive side effect of similar mechanical venti-
lation times in both groups and thus high comparability of the
investigated regimens.
Finally, as our study was conducted in one German hospital,
its results might not be directly transferable to other countries
and settings. Instead, a case-by-case check of the transferabil-
ity is advised.Critical Care    Vol 10 No 3    Muellejans et al.
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Conclusion
We conclude that analgesia and sedation with remifentanil
and propofol can facilitate a higher turnover of patients by
reducing time on mechanical ventilation and by shortening the
overall length of ICU stay compared to a conventional regimen
with midazolam and fentanyl. Higher drug costs of remifentanil
and propofol are compensated by reduced personnel costs on
the basis of earlier discharge and may even lead to cost-sav-
ings to the hospital, depending on the dosing algorithm.
Remifentanil and propofol are useful tools for analgesia and
sedation during the weaning phase and for short to medium
term sedation in the ICU.
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